TD Cowen: 'Own Apogee Therapeutics Inc (APGE)'

TD Cowen analyst Tyler Van Buren reiterated a Buy rating and {REMOVEPT} price target on Apogee Therapeutics Inc (NASDAQ: APGE).

The analyst commented: "Phase II AD Data Preview: One of the More Value-Creating Catalysts This Year; 16-week data from Part A of the APG777 Phase II trial in AD are expected in early summer. We have a high level of confidence in efficacy comparable to lebri and dupi, which could lead to up to 80%+ utilization per some KOLs given its Q3M+ dosing, in what could eventually be a $50B market. 30-40% greater exposure could lead to improved efficacy, and Part B provides a strong safety net. Own APGE."

For an analyst ratings summary and ratings history on Apogee Therapeutics Inc click here. For more ratings news on Apogee Therapeutics Inc click here.

Shares of Apogee Therapeutics Inc closed at $42.02 yesterday.

You May Also Be Interested In

• Chevron signed an agreement with Iraq's Basra Oil Company to advance commercial negotiations for West Qurna 2
• Uber (UBER) Reiterated at Market Outperform by Citizens on Delivery Hero Deal
• U.S. sending dozens more refueling planes to Israel ahead of possible escalation - Axios